FTC Scrutiny Casts Doubt On Plavix Settlement

Law360, New York (July 11, 2006, 12:00 AM EDT) -- A revamped deal designed to preserve two drug giants’ hold on the lucrative market for the blockbuster drug Plavix could fall to pieces under the weight of an earlier antitrust settlement with the Federal Trade Commission.

The latest run-in with government antitrust regulators highlights the controversial nature of settlements between brand-name drug companies and their generic competitors, experts say.

Earlier this month, the Supreme Court refused to hear a key case involving such settlements, but the issue is far from settled, as the Plavix case underscores....
To view the full article, register now.